These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 28196735)

  • 1. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
    Esquerré M; Bouillette-Marussig M; Goubier A; Momot M; Gonindard C; Keller H; Navarro A; Bissery MC
    PLoS One; 2017; 12(3):e0174038. PubMed ID: 28301611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
    Van Damme P; Bouillette-Marussig M; Hens A; De Coster I; Depuydt C; Goubier A; Van Tendeloo V; Cools N; Goossens H; Hercend T; Timmerman B; Bissery MC
    Clin Cancer Res; 2016 Jul; 22(13):3238-48. PubMed ID: 27252412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.
    Zhao L; Liu B; Ren J; Feng J; Pang Z; Gao J; Zhang H; Tan W; Tian H; Ruan L
    Virol J; 2011 Jun; 8():302. PubMed ID: 21672263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model.
    Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
    Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice.
    Mohseni AH; Razavilar V; Keyvani H; Razavi MR; Khavari-Nejad RA
    J Med Virol; 2019 Feb; 91(2):296-307. PubMed ID: 30192395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
    Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.